Actively Recruiting

Age: 50Years - 80Years
All Genders
Healthy Volunteers
ID07374705

Disentangling the Effect of Brain Insulin Resistance on Brain Health (BIR-BrainHealth)

Led by Henrik Bo Wiberg Larsson · Updated on 2026-02-25

150

Participants Needed

3

Research Sites

13 weeks

Total Duration

On this page

Sponsors

H

Henrik Bo Wiberg Larsson

Lead Sponsor

S

Steno Diabetes Center Copenhagen

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are investigating how brain insulin resistance (BIR) may contribute to cognitive decline and dementia risk in people with diabetes. The study focuses on participants with type 1 diabetes, type 2 diabetes, and healthy controls aged 50 to 80 years. It aims to understand the link between BIR, brain blood vessel dysfunction, and brain health by combining cognitive testing with advanced brain imaging and metabolic analyses. Participants will undergo MRI brain scans to assess brain insulin response, structural changes, and cerebrovascular function. Intranasal insulin will be administered to evaluate cerebral perfusion. Additional tests include advanced MRI techniques for cerebrovascular assessments and functional MRI during glucose ingestion. Blood, urine, and stool samples will be collected for biomarker and multi-omics analyses to characterize BIR. During the study, participants will complete a comprehensive battery of cognitive tests covering memory, executive function, attention, and processing speed. Researchers will collect clinical data about diabetes duration and severity. They will measure brain insulin response and cerebrovascular reactivity and correlate these with cognitive performance. The study includes safety monitoring and will last until 2032, with baseline assessments performed once per participant.

CONDITIONS

Brief Title

Disentangling the Effect of Brain Insulin Resistance on Brain Health

Who Can Participate

Age: 50Years - 80Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 50 and 80 years
  • Diagnosis of type 1 diabetes or type 2 diabetes for diabetes participants
  • Diabetes duration of at least 10 years for type 1 diabetes
  • Diabetes duration of at least 5 years for type 2 diabetes
Not Eligible

You will not qualify if you...

  • HbA1c greater than 100 mmol/mol
  • Diagnosis of diabetes other than type 1 or type 2
  • Weight over 140 kg
  • Treatment with drugs that cannot be paused for 12 hours
  • Diagnosis of dementia
  • Active or recent malignant disease within the past year
  • History of major stroke
  • Major depression or treatment with antipsychotics
  • History of traumatic brain injury
  • Other medical conditions that prevent study compliance or pose safety risks
  • Inability to perform neuropsychological tests due to severe vision, hearing impairment, or language barriers
  • Severe claustrophobia
  • Metal implants preventing brain MRI scans
  • Participants who do not wish to be informed about MRI incidental findings
  • Estimated glomerular filtration rate (eGFR) below 45 within 3 months of study visit

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - 1 day

Participants undergo cognitive testing and advanced MRI scanning to assess brain insulin resistance, brain structure, and cerebrovascular function.

1 visit (in-person)

Sample Collection

Duration - 1 day

Blood, urine, and stool samples are collected for biomarker development and multi-omics analyses.

1 visit (in-person)

Trial Site Locations

Total: 3 locations

1

Rigshospitalet

Glostrup Municipality, Denmark, 2600

Actively Recruiting

2

Steno Diabetes Center Copenhagen

Herlev, Denmark, 2730

Actively Recruiting

3

University of Ulm

Ulm, Germany, 89081

Actively Recruiting

Loading map...

Research Team

H

Henrik BW Larsson, Professor

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

3

Similar Trials

Semaglutide and Empagliflozin Combination Therapy Added to A...

Diabetes Type 1

Actively Recruiting

1 location

Efficacy and Safety of the Artificial Intelligence-assisted ...

Diabetes Type 2

Actively Recruiting

1 location

Canagliflozin Targeting Vascular Inflammation: An Ottawa Ima...

Diabetes Type 2

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here